Ruthenium Complexes as Protein Kinase Inhibitors

Replacing complex natural products with simple metal complexes could lead to a new class of metallopharmaceuticals in which the metal
center plays mainly a structural role. A strategy is introduced for the creation of ruthenium complex-based protein kinase inhibitors 1 (X =
CO or CH2), morphed out of the class of indolocarbazole inhibitors with the alkaloid staurosporine as its most prominent member.